Skip to main content

Table 3 Association between MMP2 overexpression and survival in patients with breast cancer

From: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

Survival Subgroup No. of studies No. of patients I2 (%) P for heterogeneity Pooled HR (95%CI) P for effect size
DFS Overall 3 240 0 0.724 1.79 (0.90–3.54) 0.096
OS Overall 14 2128 30.6 0.131 1.60 (1.33–1.94) < 0.001
Ethnicity       
Caucasians 7 1100 0 0.569 2.21 (1.47–3.06) < 0.001
Asians 7 1028 47.5 0.075 1.75 (1.14–2.70) 0.011
IHC analysis standard       
Percentage 7 1228 0 0.729 1.97 (1.46–2.68) < 0.001
SI 7 900 53.2 0.046 1.87 (1.08–3.26) 0.026
HR data       
Reported 9 1706 51.5 0.036 1.95 (1.37–2.79) < 0.001
Estimated 5 422 0 0.641 1.90 (0.89–4.07) 0.097
Analysis model       
Univariate 9 1245 32.2 0.160 1.52 (1.19–1.94) 0.001
Multivariate 6 1153 29.9 0.211 1.78 (1.33–2.39) < 0.001
Sample size       
> 150 5 796 23.3 0.266 1.43 (1.15–1.78) 0.002
≤150 9 1332 20.2 0.263 2.19 (1.53–3.13) < 0.001
Cancer subtype       
IDC 4 621 48.0 0.123 1.35 (1.06–1.73) 0.017
RFS Overall 5 712 0 0.892 1.21 (0.82–1.81) 0.338
  1. OS overall survival, DFS disease-free survival, RFS recurrence-free survival, IHC immunohistochemistry, IDC infiltrating ductal carcinoma, SI staining index, HR hazard ratio